AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
September 21, 2022 08:30 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life...
AVEO Oncology Announces Participation at Investor Conferences in September
August 31, 2022 08:30 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life...
AVEO Oncology Reports Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
AVEO Pharmaceuticals, Inc.
– Total Q2 2022 Net Revenue of $25.3 million including $25.0 million of FOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q2 2022 FOTIVDA U.S. Net Product Revenue Growth of 24% Compared with Q1...
AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022
July 28, 2022 16:05 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report second quarter 2022...
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
June 22, 2022 08:00 ET
|
AVEO Pharmaceuticals, Inc.
- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently...
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
June 21, 2022 08:00 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network®...
AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting
June 06, 2022 08:00 ET
|
AVEO Pharmaceuticals, Inc.
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib ...
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:30 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will...
AVEO Oncology Reports First Quarter 2022 Financial Results
May 05, 2022 07:00 ET
|
AVEO Pharmaceuticals, Inc.
– Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – –...
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
April 28, 2022 08:30 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022...